CL2023000765A1 - Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq2.5 y uso para tratar enfermedad celíaca - Google Patents
Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq2.5 y uso para tratar enfermedad celíacaInfo
- Publication number
- CL2023000765A1 CL2023000765A1 CL2023000765A CL2023000765A CL2023000765A1 CL 2023000765 A1 CL2023000765 A1 CL 2023000765A1 CL 2023000765 A CL2023000765 A CL 2023000765A CL 2023000765 A CL2023000765 A CL 2023000765A CL 2023000765 A1 CL2023000765 A1 CL 2023000765A1
- Authority
- CL
- Chile
- Prior art keywords
- hla
- celiac disease
- human leukocyte
- leukocyte antigen
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157873 | 2020-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000765A1 true CL2023000765A1 (es) | 2023-11-03 |
Family
ID=80739984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000765A CL2023000765A1 (es) | 2020-09-18 | 2023-03-16 | Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq2.5 y uso para tratar enfermedad celíaca |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11739153B2 (https=) |
| EP (1) | EP4214236A4 (https=) |
| JP (2) | JP7147030B2 (https=) |
| KR (2) | KR20230116942A (https=) |
| CN (3) | CN116096757B (https=) |
| AR (1) | AR123537A1 (https=) |
| AU (2) | AU2021343008B2 (https=) |
| CA (1) | CA3192661A1 (https=) |
| CL (1) | CL2023000765A1 (https=) |
| CO (1) | CO2023003681A2 (https=) |
| CR (1) | CR20230166A (https=) |
| IL (1) | IL301326A (https=) |
| MX (1) | MX2023002191A (https=) |
| PE (1) | PE20231208A1 (https=) |
| TW (2) | TWI820484B (https=) |
| WO (1) | WO2022059766A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020204054A1 (en) * | 2019-04-01 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| KR20230116942A (ko) * | 2020-09-18 | 2023-08-04 | 추가이 세이야쿠 가부시키가이샤 | 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 |
| KR102614250B1 (ko) * | 2021-10-08 | 2023-12-15 | 추가이 세이야쿠 가부시키가이샤 | 항hla-dq2.5 항체의 제제 |
| EP4413998A4 (en) * | 2021-10-08 | 2026-02-25 | Chugai Pharmaceutical Co Ltd | METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION |
| WO2026022921A1 (ja) * | 2024-07-23 | 2026-01-29 | 中外製薬株式会社 | 抗体の製造方法 |
| WO2026044027A1 (en) * | 2024-08-20 | 2026-02-26 | Victor Raso | Major histocompatibility complex peptides as therapeutic targets for autoimmune diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| CA2443886A1 (en) | 2001-04-12 | 2002-10-24 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| AU2009210741A1 (en) | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| AU2013204429B9 (en) | 2008-11-30 | 2017-01-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| EP2437780B1 (en) | 2009-06-04 | 2016-03-23 | The Regents of the University of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| JP2013541937A (ja) | 2010-08-05 | 2013-11-21 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質 |
| CN109134658B (zh) * | 2011-10-31 | 2022-10-14 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| WO2016202805A2 (en) | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| US20200040085A1 (en) * | 2017-02-27 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease |
| CN117777294A (zh) | 2017-10-03 | 2024-03-29 | 中外制药株式会社 | 抗hla-dq2.5抗体 |
| GB201802338D0 (en) * | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| WO2020204054A1 (en) * | 2019-04-01 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| KR20230116942A (ko) | 2020-09-18 | 2023-08-04 | 추가이 세이야쿠 가부시키가이샤 | 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 |
-
2021
- 2021-09-17 KR KR1020237024631A patent/KR20230116942A/ko active Pending
- 2021-09-17 CN CN202180061976.8A patent/CN116096757B/zh active Active
- 2021-09-17 TW TW110134821A patent/TWI820484B/zh active
- 2021-09-17 TW TW112137009A patent/TW202402804A/zh unknown
- 2021-09-17 EP EP21869449.5A patent/EP4214236A4/en active Pending
- 2021-09-17 US US17/477,651 patent/US11739153B2/en active Active
- 2021-09-17 CR CR20230166A patent/CR20230166A/es unknown
- 2021-09-17 KR KR1020217042982A patent/KR102559128B1/ko active Active
- 2021-09-17 CN CN202311818773.6A patent/CN117801115A/zh active Pending
- 2021-09-17 MX MX2023002191A patent/MX2023002191A/es unknown
- 2021-09-17 CN CN202311813323.8A patent/CN117801114A/zh active Pending
- 2021-09-17 AU AU2021343008A patent/AU2021343008B2/en active Active
- 2021-09-17 PE PE2023001173A patent/PE20231208A1/es unknown
- 2021-09-17 IL IL301326A patent/IL301326A/en unknown
- 2021-09-17 JP JP2021151709A patent/JP7147030B2/ja active Active
- 2021-09-17 AR ARP210102585A patent/AR123537A1/es unknown
- 2021-09-17 CA CA3192661A patent/CA3192661A1/en active Pending
- 2021-09-17 WO PCT/JP2021/034240 patent/WO2022059766A1/en not_active Ceased
-
2022
- 2022-09-02 JP JP2022139889A patent/JP7840234B2/ja active Active
-
2023
- 2023-03-16 CL CL2023000765A patent/CL2023000765A1/es unknown
- 2023-03-23 CO CONC2023/0003681A patent/CO2023003681A2/es unknown
- 2023-07-05 US US18/346,975 patent/US20230357408A1/en active Pending
-
2026
- 2026-01-22 AU AU2026200463A patent/AU2026200463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230116942A (ko) | 2023-08-04 |
| AR123537A1 (es) | 2022-12-14 |
| JP2022172276A (ja) | 2022-11-15 |
| AU2021343008A1 (en) | 2023-06-01 |
| CR20230166A (es) | 2023-05-31 |
| TWI820484B (zh) | 2023-11-01 |
| CN116096757A (zh) | 2023-05-09 |
| TW202402804A (zh) | 2024-01-16 |
| CN117801115A (zh) | 2024-04-02 |
| US20220089743A1 (en) | 2022-03-24 |
| CN116096757B (zh) | 2024-01-12 |
| AU2021343008A9 (en) | 2024-10-10 |
| JP7147030B2 (ja) | 2022-10-04 |
| AU2021343008B2 (en) | 2025-11-13 |
| EP4214236A4 (en) | 2024-10-30 |
| CN117801114A (zh) | 2024-04-02 |
| JP2022051553A (ja) | 2022-03-31 |
| EP4214236A1 (en) | 2023-07-26 |
| AU2026200463A1 (en) | 2026-02-12 |
| US11739153B2 (en) | 2023-08-29 |
| WO2022059766A1 (en) | 2022-03-24 |
| KR102559128B1 (ko) | 2023-07-24 |
| IL301326A (en) | 2023-05-01 |
| PE20231208A1 (es) | 2023-08-17 |
| JP7840234B2 (ja) | 2026-04-03 |
| US20230357408A1 (en) | 2023-11-09 |
| MX2023002191A (es) | 2023-03-03 |
| TW202229345A (zh) | 2022-08-01 |
| CA3192661A1 (en) | 2022-03-24 |
| KR20220153469A (ko) | 2022-11-18 |
| CO2023003681A2 (es) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000765A1 (es) | Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq2.5 y uso para tratar enfermedad celíaca | |
| PE20131376A1 (es) | Anticuerpos para metaloproteinasa-9 de matriz | |
| CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| MX2018014979A (es) | Anticuerpos específicos dirigidos contra hla-g. | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| MX2021009722A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| AR122111A1 (es) | ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS | |
| CO2022000804A2 (es) | Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| CL2023001377A1 (es) | Anticuerpos anti-npr1 y usos de los mismos | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| MX2023014679A (es) | Peptidos grapados y metodos para su obtencion. | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| BR112014024751A2 (pt) | antígenos de clostridium difficile | |
| CL2024001304A1 (es) | Anticuerpos anti-cd19 humano | |
| CO2022008314A2 (es) | Anticuerpos anti–mertk y métodos de uso de los mismos | |
| MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
| MX2023006869A (es) | Proteinas de union condicionalmente biespecificas. | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| CO2023012831A2 (es) | Anticuerpo anti componente del complemento 1s (c1s) | |
| MX2024005511A (es) | Anticuerpo mica con maduracion de afinidad y uso del mismo | |
| MX2022001305A (es) | Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo. | |
| EA202092698A1 (ru) | Искусственный белок, содержащий антигенсвязывающую область антитела, слитый с биоактивными пептидами | |
| MX2022011591A (es) | Anticuerpos anti-ceramida. |